Unlock Editor’s Digest Lock for Free
FT editor Roula Khalaf will select your favorite stories in this weekly newsletter.
Astrazeneca has released positive test results for breast cancer drugs that can stop mutations in mutations before the tumor begins to grow. We hope that it will become one of our portfolios of medicines that will drive it to become a global leader in oncology.
The late-stage trial of “progressive” breast cancer, presented at the annual ASCO Cancer Conference, reduced the risk of tumor progression or dying patients by 56%. Astrazeneca estimates it is worth up to $5 billion in sales at its peak.
David Fredrickson, Vice President of Oncology at Astrazeneca, said Camizestrant and two other drugs presented at the conference could replace existing treatments with up to 75,000 patients between them.
AstraZeneca’s ambition was to become the “number one cancer company in the world” through sales. Currently, it is third in some regions. The Pharma group already has nine cancer drugs approved at 37 cancer stages and stages.
The Camidestrand study used an innovative blood test, often called liquid biopsies, to detect tumor DNA and identify patients at high risk for mutant tumors before being picked up on a scan. This test allowed patients to be treated with new medication early on.
“We’re moving from an era that’s perfect for all sizes to where we can remove the mechanism of cancer resistance before it actually settles,” Fredrickson said.
This study treated a subset of breast cancer patients with tumor-specific receptors. Kamiséstrand prevents estrogen from attaching to cancer cells and destroys cellular receptors, making it difficult to resist treatment.
The results showed that disease progression in patients taking new medications in combination with existing treatments was delayed by an average of 16 months compared to 9.2 months in the group, taking existing treatments alone.
The trial also found that treatment with new drugs improves the quality of life for patients significantly longer than current standards. Comprehensive data on how useful the medication can help patients survive compared to existing treatments is not yet published.
The study was led by researchers at the Cancer Institute in London, the Royal Marsden NHS Foundation Trust in London, and the Institute Curie in Paris.
Professor Christian Herrin, CEO of the Cancer Institute, said the results were “more than a clinical milestone and represent a transformative change in the way we approach precision medicine.”
